Article

First Patient Randomized in Phase 2 Trial for NSCLC Treatment Combination

Author(s):

The first patient was randomized in the phase 2 trial examining Tedopi and Opdivo for non-small cell lung cancer.

OSE Immunotherapeutics SA and the FoRT Foundation announced last week that the first patient was randomized to receive treatment in the phase 2 trial of Tedopi and Opdivo (nivolumab).

The combination therapy will be given as a second-line treatment to patients with HLA-A2-positive metastatic non-small cell lung cancer (NSCLC). Patients will be randomized to receive either Tedopi and Opdivo – which is a PD-1 targeted checkpoint immune inhibitor – , Tedopi plus chemotherapy or chemotherapy alone.

Tedopi is a neo-epitope-based vaccine that activates T lymphocytes, which researchers hope will optimize the checkpoint inhibitor or chemotherapy in patients who have become resistant.

“We look forward to evaluating this second-line combination of immuno-therapeutic agents in NSCLC patients with disease progression, a population who needs new treatment options,” said Dr. Federico Cappuzzo, director of medical oncology at Cancer Institute Regina Elena, in a release.

The trial will have 105 patients, and results are expected in 2024.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
Image of two doctors and text.
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of doctor.
Image of Dr. Boffa.
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Image of Dr. Reznick
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.